Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct 7;2009(4):CD003422.
doi: 10.1002/14651858.CD003422.pub4.

Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss

Lekha Agarwal  1 , David D Pothier
Affiliations

Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss

Lekha Agarwal et al. Cochrane Database Syst Rev. .

Abstract

Background: Idiopathic sudden sensorineural hearing loss (ISSHL) is sudden hearing loss where clinical assessment fails to reveal a cause. The most widely used therapeutic agents for ISSHL are antivirals, steroids, hyperbaric oxygen, vasodilators and rheological/vasoactive substances. There is currently conflicting evidence for vasodilator and vasoactive substances in the treatment of ISSHL.

Objectives: 1. To determine the effectiveness of vasodilators and other vasoactive substances in improving hearing in patients with ISSHL. 2. To determine the adverse effects of these medications.

Search strategy: We searched the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL); PubMed; EMBASE; CINAHL; Web of Science; Cambridge Scientific Abstracts; mRCT and additional sources for published and unpublished trials. The date of the most recent search was 16 September 2008.

Selection criteria: Randomised controlled trials (RCTs) of vasodilators/vasoactive substance versus placebo in the treatment of ISSHL. Trials were assessed for methodological quality.

Data collection and analysis: The authors assessed trials and extracted data independently. We contacted investigators to obtain additional information where necessary. Meta-analysis was neither possible nor considered appropriate due to the differences in the type of vasodilators used, dosage and duration of treatment. The quality and the result of each study was analysed and reported individually.

Main results: Only three trials, involving 189 participants, satisfied the inclusion criteria and these were of low methodological quality. One study showed a significant difference in hearing recovery in the vasodilator group (carbogen combined with a course of several other drugs) compared to the control group (a course of several other drugs alone). Another study only showed a significant improvement in higher frequencies in the vasodilator group (prostaglandin E1 + steroid) compared with the control group (placebo and steroid), no difference having been shown in overall hearing gain. In the third study the vasodilator group (naftidrofuryl and low-molecular weight dextran) showed an improvement only in lower frequencies over the control group (placebo and low-molecular weight dextran).Two of the studies reported adverse effects from vasodilator treatment, whereas there was no mention of any side effects in the third. Five patients in one study developed a sensation of heaviness in the head which settled spontaneously and did not interfere with treatment. In the other study one patient developed an allergic reaction and had to be excluded from the study.

Authors' conclusions: The effectiveness of vasodilators in the treatment of ISSHL remains unproven. The included studies were of relatively poor quality and the number of patients included was small. Moreover, there were differences in the type, dosage and duration of vasodilator used in each study. Due to the degree of heterogeneity the results could not be combined to reach a conclusion.

PubMed Disclaimer

Conflict of interest statement

None known.

Update of

References

References to studies included in this review

Ni 2004 {published data only}
    1. Ni Y, Zhao X. Carbogen combined with drugs in the treatment of sudden deafness. Lin Chuang Er Bi Yan Hou Ke Za Zhi [Journal of Clinical Otorhinolaryngology] 2004;18(7):414‐5. - PubMed
Ogawa 2002 {published data only}
    1. Ogawa K, Takei S, Inoue Y, Kanzaki J. Effect of prostaglandin E1 on idiopathic sudden sensorineural hearing loss: a double‐blinded clinical study. Otology and Neurotology 2002;23:665‐8. - PubMed
Poser 1992 {published data only}
    1. Poser R, Hirche H. A randomized, double‐blind study for the treatment of sudden deafness: low‐molecular weight dextran and naftidrofuryl versus low‐molecular weight dextran and placebo. HNO 1992;40:396‐9. - PubMed

References to studies excluded from this review

Ahn 2005 {published data only}
    1. Ahn JH, Kim MR, Kim HC. Therapeutic effect of lipoprostaglandin E1 on sudden hearing loss. American Journal of Otolaryngology 2005;26:245‐8. - PubMed
Ahn 2006 {published data only}
    1. Ahn JH, Kim TY, Kim YJ, Han MW, Yoon TH, Chung JW. Lipo‐prostaglandin E1 in combination with steroid therapy is effective for treatment of sudden sensorineural hearing loss in Korean patients with Type 2 diabetes. Diabetic Medicine 2006;23:1339‐43. - PubMed
Cesarone 2002 {published data only}
    1. Cesarone MR, Incandela L, Belcaro G, Sanctis MT, Nicolaides MN, Griffin M, et al. Treatment of vascular inner ear disease in vascular patients with pentoxifylline: a controlled, randomized trial. Angiology 2002;53(Suppl 1):S23‐6. - PubMed
Cinamon 2001 {published data only}
    1. Cinnamon U, Bender E, Kronanberg J. Steroids, carbogen or placebo for sudden hearing loss: a prospective double‐blind study. European Archives of Oto‐Rhino‐Laryngology 2001;258:477‐80. - PubMed
Desloovere 1989 {published data only}
    1. Desloovere C, Lorz M, Klima A. Sudden sensorineural hearing loss influence of hemodynamical and hemorheological factors on spontaneous recovery and therapeutic results. Acta Oto‐Rhino‐Laryngologica Belgica 1989;43(1):31‐7. - PubMed
Dubreuil 1986 {published data only}
    1. Dubreuil C. Therapeutic trial in acute cochlear deafness. A comparative study of Ginkgo biloba extract and nicergoline [Essai therapeutique dans les surdites cochleaires aigues. Etude comparative de l'extrait de Ginkgo biloba et de la nicergoline]. Presse Medicale 1986;15(31):1559‐61. - PubMed
Fisch 1983 {published data only}
    1. Fisch U. Management of sudden deafness. Otolaryngology ‐ Head and Neck Surgery 1983;91:3‐8. - PubMed
Friedrich 1991 {published data only}
    1. Friedrich G, Ott E. Prospective randomized study on the comparative effect between 10% HES 200/0.5 and 6% HES 200/0.5 in patients with hearing loss [Prospektiv randomisierte Studie zum Wirkungsvergleich zwischen 10 percent HES 200/0.5 und 6 percent HES 200/0.5 bei Horsturzpatienten]. Laryngo‐Rhino‐otologie 1991;70:670‐4. - PubMed
Giger 1979 {published data only}
    1. Giger HL. Horsturztherapie mit Oxycarbon‐Inhalation. HNO 1979;27:107‐9. - PubMed
Gutman 1995 {published data only}
    1. Gutmann R, Mees K. Treatment of acute tinnitus and sudden hearing loss with infusion of piracetam. Fortschritte der Medizin 1895;113:34‐6. - PubMed
Hoffmann 1994 {published data only}
    1. Hoffmann F, Beck C, Schutz A, Offermann P. Ginkgo extract EGb 761 (tenobin)/HAES versus naftidrofuryl (Dusodril)/HAES. A randomized study of therapy of sudden deafness [Ginkgoextrakt EGb 761 (Tebonin)/HAES versus Naftidrofuryl (Dusodril)/HAES. Eine randomisierte Studie zur Horsturztherapie]. Laryngo‐Rhino‐Otologie 1994;73:149‐52. - PubMed
Kallinen 1997 {published data only}
    1. Kallinen J, Laurikainen E, Laippala P, Grénman R. Sudden deafness: a comparison of anticoagulant therapy and carbogen inhalation therapy. Annals of Otology, Rhinology and Laryngology 1997;106:22‐6. - PubMed
Kanzaki 2003 {published data only}
    1. Kanzaki J, Inoue Y, Ogawa K, Fukuda S. Effect of single‐drug treatment on sudden sensorineural hearing loss. Auris Nasus Larynx 2003;30:123‐7. - PubMed
Kronenberg 1992 {published data only}
    1. Kronenberg J, Almagor M, Bendet E, Kushnir D. Vasoactive therapy versus placebo in the treatment of sudden hearing loss: a double‐blind clinical study. Laryngoscope 1992;102:65‐8. - PubMed
Lenarz 1989 {published data only}
    1. Lenarz T. Treatment of sudden hearing loss with the calcium antagonist nimodipine. Laryngorhinootologie 1989;68(11):634‐7. - PubMed
Mann 1986 {published data only}
    1. Mann W, Beck C, Beck C. Calcium antagonists in the treatment of sudden deafness. Archives of Otorhinolaryngology 1986;243(3):170‐3. - PubMed
Nakashima 1989 {published data only}
    1. Nakashima T, Kuno K, Yanagita N. Evaluation of prostaglandin E1 therapy for sudden deafness. Laryngoscope 1989;99(5):542‐6. - PubMed
Reisser 2001 {published data only}
    1. Reisser CH, Weidauer H. Ginkgo biloba extract EGb 761 or pentoxifylline for the treatment of sudden deafness: a randomized, reference‐controlled, double‐blind study. Acta Oto‐laryngologica 2001;121(5):579‐84. - PubMed

References to studies awaiting assessment

Dauman 1985 {published data only}
    1. Dauman R, Cros AM, Poisot D. Treatment of sudden deafness: first results of a comparative study [Traitements des surdites brusques: Premiers resultats d'une etude comparative]. Journal of Otolaryngology 1985;14:49‐56. - PubMed
Edamatsu 1985 {published data only}
    1. Edamatsu H, Hasegawa M, Oku T, Nigauri T, Kurita N, Watanabe I. Treatment of sudden deafness: carbon dioxide and oxygen inhalation and steroids. Clinical Otolaryngology and Allied Sciences 1985;10:69‐72. - PubMed
Fattori 2001 {published data only}
    1. Fattori B, Berrettini S, Casani A, Nacci A, Vito A, Iaco G. Sudden hypoacusis treated with hyperbaric oxygen therapy: a controlled study. Ear Nose and Throat Journal 2001;80:655‐60. - PubMed
Koehn 1985 {published data only}
    1. Koehn W, Nickol HJ, Horsturz. Zur Altersabhangigkeit der Therapieergebnisse unter Berucksichtigung von Naftidrofuryl (Dusodril). HNO 1985;33:36‐9. - PubMed
Mora 2006 {published data only}
    1. Mora R, Dellepiane M, Mora F, Jankowska B. Sodium enoxaparin and venovenous hemofiltration in treating sudden sensorineural hearing loss and tinnitus. International Tinnitus Journal 2006;12:83‐6. - PubMed

Additional references

Chalmers 1990
    1. Chalmers I, Adams M, Dickersin K, Hetherington J, Tarnow‐Mordi W, Meinert C, et al. A cohort study of summary reports of controlled trials. JAMA 1990;263:1401‐5. - PubMed
Cole 1988
    1. Cole RR, Jahrsdoerfer RA. Sudden hearing loss: an update. American Journal of Otology 1988;9(3):211‐5. - PubMed
Fisch 1976
    1. Fisch U, Murata K, Hossli G. Measurement of oxygen tension in human perilymph. Acta Oto‐laryngologica (Stockh) 1976;81:278‐82. - PubMed
Gates 2000
    1. Gates G. In: Canalis RF, Lambert PR editor(s). The ear: comprehensive otology. Philadelphia: Lippincott Williams and Wilkins, 2000.
Handbook 2008
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Hughes 1996
    1. Hughes GB, Freedman MA, Haberkamp TJ, Guay ME. Sudden sensorineural hearing loss. Otolaryngologic Clinics of North America 1996;29(3):394‐405. - PubMed
Laskawi 1987
    1. Laskawi R, Schrader B, Schroder M, Poser R, Brelie R. Therapy of hearing loss ‐ naftidrofuryl compared with pentoxifyllin. Laryngologie, Rhinologie, Otologie 1987;66:242‐5. - PubMed
Mattox 1980
    1. Mattox DE. Medical management of sudden hearing loss. Otolaryngology ‐ Head and Neck Surgery 1980;88:111‐3. - PubMed
Mattox 1989
    1. Mattox DE, Lyles CA. Idiopathic sudden sensorineural hearing loss. American Journal of Otology 1989;10(3):242‐7. - PubMed
Miller 1988
    1. Miller J, Dengerink H. Control of inner ear blood flow. Annals of Otology, Rhinology and Laryngology 1988;9:302‐16. - PubMed
Moher 2001
    1. Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA 2001;285(15):1987‐91. - PubMed
RevMan 2008 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Shambaugh 1990
    1. Shambaugh GE, Glasscock ME. Surgery of the Ear. Philadelphia: Saunders, 1990.
Shikowitz 1991
    1. Shikowitz MJ. Sudden sensorineural hearing loss. Medical Clinics of North America 1991;75(6):1239‐50. - PubMed
Stokroos 1996
    1. Stokroos RJ, Albers FWJ. The etiology of idiopathic sudden sensorineural loss. A review of the literature. Acta Oto‐rhino‐laryngologica Belgica 1996;50(1):69‐76. - PubMed
Suckfull 2002
    1. Suckfull M, Seidel D, Thiery J, Mazurek B, Jaehne M, Gronemeyer J, et al. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multi centre trial. Lancet 2002;360:1811‐7. - PubMed
Thurmond 1998
    1. Thurmond M, Amedee RG. Sudden sensorineural hearing loss: etiologies and treatments. Journal of the Louisiana State Medical Society 1998;150(5):200‐3. - PubMed
Wei 2006
    1. Wei BPC, Mubiru S, O'Leary S. Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database of Systematic Reviews 2006, Issue 1. [Art. No.: CD003998. DOI: 10.1002/14651858.CD003998.pub2] - PubMed

Publication types

MeSH terms

LinkOut - more resources